



Restore Vision 20/20 – Full Grant Application Instructions

DEADLINE IS June 25, 2018, 5 pm (EST). Submit a single PDF online: ffb.ca/research/for-researchers/

Prior to beginning an application, please review the ***Restore Vision 20/20 Initiative General Guidelines AND Evaluation Process & Review Criteria.***

DISEASE FOCUS: The Restore Vision 20/20 Initiative has a primary goal to support research with the potential to impact late-stage retinitis pigmentosa (i.e., act to preserve or improve function in remaining photoreceptors and/or restore vision after all photoreceptors have been lost).

GRANT DURATION AND FUNDING: The grant is based on a 24-month funding period (October 1, 2017 to October 1, 2019) and is up to \$800,000 in value. The funding start date may be postponed up to 3 months. In addition, please prepare a high-level projected budget of up to \$400,000/year for an additional 2 years (October 1, 2019 to October 1, 2021).

Follow the formatting requirements: English; letter size pages; 12 point font; black ink; 2 cm margins; single-spaced, no condensed typing or spacing. Include the page number on the lower right hand corner and the Principal Investigator's name on the upper right hand corner of each page.

Compile the application as a single PDF document in the following order:

1	Restore Vision 20/20 Application Form (download)
2	Research Proposal (free text, 10 pages maximum not including references; plus appended material - see section 7) <ul style="list-style-type: none">• Describe the background, rationale and objectives of the project• Outline the research approach and methodology; explain how the expertise of co-applicants and collaborators will contribute to success• Highlight the project's originality and potential clinical impact• Detail year 1 and year 2 milestones with timelines in reference to the long-term translation plan
3	Translation Plan (free text, 2 pages maximum): Describe how the outcomes of this project will contribute to developing a new therapy for late-stage retinitis pigmentosa (RP) and other retinal degenerative disease(s). Please note that the project must be relevant to late-stage RP. Provide an estimate of additional research and resources



	<p>that would be required to initiate a clinical trial with the proposed intervention.. If relevant, it may be useful to include comments on the following aspects of the project:</p> <ul style="list-style-type: none"> • Technology and manufacturing scale-up for clinical grade quantity and quality • Patent and intellectual property management • Commercialization plan • Regulatory approval • Clinical trials expertise (trial design and protocol; REB; DSMB; screening and recruitment; data management; monitoring; reporting; etc.) • Industry receptors and/or out-licensing and company creation • Development of a reasonable reimbursement model • Engagement of the clinical community for future adoption of technology or therapy
4	<p>Budget - Complete the excel budget template. Do not add content to the first "MASTER" worksheet – this page compiles information that is added into the worksheets for different investigators who will receive funding for the project. The grant is based on a 24-month funding period (October 1, 2017 to October 1, 2019) and is up to \$800,000 in value. In addition, please prepare a high-level projected budget of up to \$400,000/year for an additional 2 years (October 1, 2019 to October 1, 2021). Continued funding will be dependent on availability of funds, review of progress by the SAB after Year 2, and proposed future work.</p>
5	<p>Budget Justification (free text, 2 pages maximum) Explain the staffing and resources requested in the previous section.</p>
6	<p>CVs for the principal applicant and co-applicants. Use the NIH Biosketch format, or other free text format that you judge pertinent to highlight your most significant achievements (5 pages max).</p>
7	<p>Appended materials (10 pages maximum) – May include: tables, charts, figures and photographs supporting the material in the Research Proposal. Legends should briefly and succinctly describe the Figure and should not be relied on to convey major details of the project's methods.</p>
8	<p>Letters of Support - May include letters from collaborators that are not listed on the application and who will be providing essential reagents and/or technical support.</p>

Questions? Please contact: Mary Sunderland, Director of Research & Education, Foundation Fighting Blindness 416-360-4200 x238 or 1-800-461-3331 x238; msunderland@ffb.ca